X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical

Yuvraj_pawp by Yuvraj_pawp
4th September 2014
in Americas, News

The board of directors of Luye Pharma Group Ltd., announced yesterday that the Company had entered into an agreement to purchase 57.98% stake of Beijing Jialin Pharmaceutical Co., Ltd. (Jialin Pharmaceutical) for an aggregate consideration of RMB 3.68 billion in cash. The acquisition will add another key product to the Company’s portfolio and enrich product line of cardiovascular system, which is the strategic therapeutic focus of the Company. This acquisition will further strengthen Company’s market position and competitive advantage in cardiovascular system, especially in the area of lipid regulators, and thus maximize the Company’s size and strengths swiftly.

The Company focuses on the development, production, marketing and selling of innovative products in oncology, cardiovascular system, and alimentary tract and metabolism. Cardiovascular system is one of the Company’s key therapeutic area. Jialin Pharmaceutical is a leading player in the PRC pharmaceutical sector principally engaged in the pharmaceutical products in cardiovascular systems. Its leading product in cardiovascular system has become the main product in the area of lipid regulators in China. In addition, Jialin Pharmaceutical has a variety of products in cardiovascular system and its key areas are in tandem with the Company.

According to China Medical and Pharmaceutical Economic Information Network (MENET), cardiovascular system was the third largest overall therapeutic area for pharmaceutical products in China in 2013 in terms of revenue, accounting for 14.4% of the market. The Company’s key cardiovascular system products include Xuezhikang, which is the most influential and best-selling lipid regulators Chinese medicine. Xuezhikang is listed in the National List of Essential Drugs and enjoys exclusivity in China. Jialin Pharmaceutical has the leading product in cardiovascular system .The Company believes that the acquisition will supplement the Company’s already existing cardiovascular system product portfolio, help drive the Company’s market share, significantly increase its strategic competitiveness in the cardiovascular system market, especially in the area of lipid regulators. Meanwhile, the Company has Beixin((acarbose capsules used in the treatment of type 2 diabetes mellitus)–core product in alimentary tract and metabolism. The combination of three products will create substantial synergies and considerably strengthen the Company’s competitive advantage in the key strategic areas of the PRC cardiovascular system and alimentary tract and metabolism market.

The Company has a well-established nationwide sales and distribution network across 30 provinces, municipalities and autonomous regions in China. Jialin Pharmaceutical has also established a wide-coverage sales network through which it sells its products across China. Through the acquisition, the Company can further enhance its sales and marketing coverage and synergies, and take advantages of the multiple channels offered by the combined network.  

The Company develops innovative products on the back of its strong research and development capability, and believes that this will form the basis of the Company’s long-term competitiveness and serve as the drivers for the Company’s future growth and development. Jialin Pharmaceutical is a national high-tech enterprise and has rich experience and strong capabilities in product R&D. The acquisition will further enhance the Company’s research and development capability and provide valuable support to the Company’s pipeline R&D projects and other product development. 

The acquisition is in line with the Company’s strategic development needs in key therapeutic areas, key product lines, marketing and product research and development. The acquisition is conducive to maximizing the size and strength of the Company and solidifying the Company’s position in cardiovascular system. The combination of the Company and the Jialin Pharmaceutical will produce considerable synergies and fresh impetus to the Company’s better development in cardiovascular system in the future.

Tags: AmericaLuye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical
Previous Post

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

Next Post

Bayer seeks marketing authorisation of aflibercept solution for injection in Japan

Related Posts

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Next Post

Bayer seeks marketing authorisation of aflibercept solution for injection in Japan

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In